Alector (ALEC) Projected to Post Quarterly Earnings on Thursday

Key Points

• Alector will report Q1 2026 results before the market opens on May 14, with analysts forecasting EPS of ($0.2878) and revenue of $9.672 million and an investor call scheduled for May 11 at 4:00 PM ET.
• In the prior quarter Alector beat EPS estimates (reported -$0.34 vs. consensus -$0.39) and posted $6.24M in revenue, but analysts still expect roughly -$1 EPS for the current and next fiscal year.
• Market and analyst backdrop: ALEC has a ~$285M market cap, a consensus "Hold" rating with a $3.63 price target (3 Buy / 3 Hold / 2 Sell), and institutions own about 85.8% of the stock.

Alector (NASDAQ:ALEC - Get Free Report) is expected to be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Alector to post earnings of ($0.2878) per share and revenue of $9.6720 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Monday, May 11, 2026 at 4:00 PM ET.

Alector (NASDAQ:ALEC - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.05. Alector had a negative net margin of 679.16% and a negative return on equity of 224.96%. The company had revenue of $6.24 million for the quarter, compared to analyst estimates of $1.78 million. On average, analysts expect Alector to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alector Stock Performance

Shares of ALEC stock opened at $2.57 on Thursday. The stock has a market capitalization of $285.35 million, a price-to-earnings ratio of -1.85 and a beta of 0.64. The company's fifty day simple moving average is $2.31 and its two-hundred day simple moving average is $1.87. Alector has a 1 year low of $0.97 and a 1 year high of $3.40. The company has a debt-to-equity ratio of 0.30, a current ratio of 3.83 and a quick ratio of 3.83.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ALEC shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Alector in a report on Monday. Morgan Stanley reaffirmed an "underweight" rating and issued a $2.00 price target on shares of Alector in a report on Monday. Wall Street Zen downgraded Alector from a "hold" rating to a "sell" rating in a research report on Sunday, March 1st. Cantor Fitzgerald raised Alector from a "neutral" rating to an "overweight" rating in a report on Wednesday, April 15th. Finally, BTIG Research upgraded shares of Alector from a "neutral" rating to a "buy" rating and set a $6.00 price objective on the stock in a research report on Tuesday, March 10th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $3.63.

Hedge Funds Weigh In On Alector

A number of large investors have recently added to or reduced their stakes in ALEC. Graham Capital Management L.P. grew its position in shares of Alector by 394.2% in the 4th quarter. Graham Capital Management L.P. now owns 104,851 shares of the company's stock worth $164,000 after buying an additional 83,636 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of Alector during the fourth quarter valued at approximately $121,000. Wells Fargo & Company MN raised its holdings in shares of Alector by 71.9% during the fourth quarter. Wells Fargo & Company MN now owns 90,108 shares of the company's stock valued at $141,000 after acquiring an additional 37,683 shares in the last quarter. Jasper Ridge Partners L.P. lifted its stake in Alector by 32.5% in the fourth quarter. Jasper Ridge Partners L.P. now owns 95,068 shares of the company's stock worth $148,000 after acquiring an additional 23,292 shares during the period. Finally, Bridgeway Capital Management LLC purchased a new stake in Alector in the second quarter worth $161,000. Hedge funds and other institutional investors own 85.83% of the company's stock.

Alector Company Profile

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector's approach aims to harness the body's natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer's disease and frontotemporal dementia.

The company's pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer's disease studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.